Comparative efficacy and safety of fexuprazan versus esomeprazole in gastroesophageal reflux disease: a systematic review and meta-analysis
Frontiers in Medicine · 07.05.2026 · 13
DOI: 10.3389/fmed.2026.1852781 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Medicine, online erschienen am 07.05.2026. Verfasst von Omar Abureesh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Staten Island University Hospital, Staten Island, NY, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Fexuprazan is a newly emerging potassium-competitive acid blocker (P-CAB) medication. P-CAB drugs have been introduced as alternative medications for gastroesophageal reflux disease (GERD) instead of traditionally used proton-pump inhibitors (PPIs).
Aim
This study aims to compare the efficacy and safety of fexuprazan in contrast to esomeprazole.
Methods
An electronic search was conducted on major databases, and retrieved results were subjected to two stages of filtration based upon a preset inclusion criterion. The first stage filtered articles based on their titles and abstracts, and the second stage filtered articles based on their full texts. Articles found fit to include in this study were extracted using a pre-set piloted extraction form. Extraction results were introduced into a spreadsheet. Data was divided into categorical and numerical data. Categorical data was reported as counts and frequencies, while continuous data was reported as proportions, means, and standard deviations. Common and random effect meta-analyses were conducted as found fit. Risk of bias assessment was performed using the Cochrane’s risk of bias assessment (RoB 2.0) tool.
Results
Five articles were included in the present review, describing 965 patients managed with fexuprazan 40 mg or esomeprazole 40 mg for a mean of 9.6 weeks. The mean age of patients was 50.2 ± 13.0 years. GERD symptom scores showed a numerically lower value in the fexuprazan group (SMD − 0.41 [95% CI: −1.10; 0.29], p = 0.25), though this difference was not statistically significant and the confidence interval crosses the null ( I 2 = 94.5%, p < 0.01). The proportion of patients reporting symptom improvement did not differ significantly between groups (RR 0.85 [95% CI: 0.6; 1.22], p = 0.39; I 2 = 91.3%, p < 0.01). No significant difference was observed in the incidence of treatment-emergent adverse events (TEAEs; RR 1.07 [95% CI: 0.9; 1.27], p = 0.45; I 2 = 0.0%) or adverse drug reactions (ADRs; RR 1.10 [95% CI: 0.79; 1.53], p = 0.59; I 2 = 0.0%).
Conclusion
No statistically significant difference in efficacy was identified between fexuprazan and esomeprazole; however, preliminary findings are consistent with non-inferiority. No statistically significant difference in the incidence of TEAEs or ADRs was observed between treatments, suggesting a comparable safety profile. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261286108 .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Staten Island University Hospital, Staten Island, NY, United States.
- School of Medicine, The University of Jordan, Amman, Jordan.
- Department of Internal Medicine, Medstar Washington Hospital Center, Washington, DC, United States.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Hospitals, Albuquerque, NM, United States.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
- Division of Gasstroenterology and Hepatology, Department of Internal Medicine, Staten Island University Hospital, Staten Island, NY, United States.
Zitieren
APA
Abureesh, O., Sohail, A., Yousef, Y., Abureesh, A., Abdulraheem, A., Tam, R., Abou Yassine, A., Altork, N., Vankayala, U. S. A., Chalhoub, J., Andrawes, S., & El Douaihy, Y. (2026). Comparative efficacy and safety of fexuprazan versus esomeprazole in gastroesophageal reflux disease: a systematic review and meta-analysis. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1852781
Vancouver
Abureesh O, Sohail A, Yousef Y, Abureesh A, Abdulraheem A, Tam R, et al. Comparative efficacy and safety of fexuprazan versus esomeprazole in gastroesophageal reflux disease: a systematic review and meta-analysis. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1852781
BibTeX
@article{Abureesh2026,
author = {Abureesh, Omar and Sohail, Ali and Yousef, Yousef and Abureesh, Abdullah and Abdulraheem, Ahmad and Tam, Ryan and Abou Yassine, Ahmad and Altork, Nadera and Vankayala, Uday Sankar Akash and Chalhoub, Jean and Andrawes, Sherif and El Douaihy, Youssef},
title = {Comparative efficacy and safety of fexuprazan versus esomeprazole in gastroesophageal reflux disease: a systematic review and meta-analysis},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1852781}
}
EUVIMED